insights_auto
Sebab 6160 meningkat 4.36%?
Terokai Dengan Lebih Terperincichevron_right
6160:HKG
BeOne Medicines AG
HK$225.00
arrow_upward
+4.36%(+9.40) 1H
16 Okt, 4:08:14 PTG GMT+8 · HKD
search
Semua simbol
| Simbol | Harga | Perubahan | % Perubahan |
|---|
insights_autoMenjana cerapan popular untuk 6160...
Buka
HK$224.80
Tinggi
HK$230.20
Rendah
HK$221.80
Permodalan Pasaran
355.76B
Purata volum
2.93J
Volum
4.41J
Nisbah H/P
65.67
tgi 52 mgu
HK$235.60
rdh 52 mgu
HK$153.00
EPS
HK$3.43
Syer tertunggak
1.43B
Bilangan pekerja
12K
Buka
HK$224.80
Tinggi
HK$230.20
Rendah
HK$221.80
Permodalan Pasaran
355.76B
Purata volum
2.93J
Volum
4.41J
Nisbah H/P
65.67
tgi 52 mgu
HK$235.60
rdh 52 mgu
HK$153.00
EPS
HK$3.43
Syer tertunggak
1.43B
Bilangan pekerja
12K
Cerita berita
Daripada sumber web dan rakan kongsi berita
Profil
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Perihal BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Pekerja12K
Diasaskan28 Okt 2010
Ibu pejabat-
Sektor-
Laman webbeonemedicines.com